Rocket Pharmaceuticals (RCKT) EPS (Weighted Average and Diluted): 2019-2025
Historic EPS (Weighted Average and Diluted) for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Sep 2025 value amounting to -$0.45.
- Rocket Pharmaceuticals' EPS (Weighted Average and Diluted) rose 36.62% to -$0.45 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.25, marking a year-over-year increase of 17.58%. This contributed to the annual value of -$2.73 for FY2024, which is 6.51% up from last year.
- According to the latest figures from Q3 2025, Rocket Pharmaceuticals' EPS (Weighted Average and Diluted) is -$0.45, which was up 27.42% from -$0.62 recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of -$0.45 during Q3 2025, and its lowest value of -$0.89 during Q4 2022.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.66, with a median of -$0.66 in 2024.
- As far as peak fluctuations go, Rocket Pharmaceuticals' EPS (Weighted Average and Diluted) spiked by 37.61% in 2021, and later plummeted by 50.91% in 2022.
- Over the past 5 years, Rocket Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.68 in 2021, then plummeted by 30.88% to -$0.89 in 2022, then spiked by 30.34% to -$0.62 in 2023, then remained steady at -$0.62 in 2024, then skyrocketed by 36.62% to -$0.45 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.45 in Q3 2025, compared to -$0.62 in Q2 2025 and -$0.56 in Q1 2025.